588.35
-1.98%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Healthcare Global Enterprises
Its shares trade on NSE under the ticker HCG.NS. It has been listed since 30 March 2016. In the fiscal year to 31 March 2026, it reported revenue of ₹25.38bn and net income of ₹137.6m. At that date it held total assets of ₹39.23bn and shareholders' equity of ₹13.32bn.
HealthCare Global Enterprises Ltd. provides imaging and diagnostics services for cancer treatment. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2016-03-30. The firm is a provider of specialty healthcare focused on cancer and fertility. Under the HCG brand, the Company operates cancer care network in India in terms of the total number of private cancer treatment centers. The firm also provide fertility treatment under its Milann brand. Its Milann fertility centers provide reproductive medicine services, including assisted reproduction, gynecological endoscopy and fertility preservation; and follow a multidisciplinary and technology focused approach to diagnosis and treatment. Under the Triesta brand, it offers oncology diagnostics, biomarker and translational research, and laboratory services. The firm also operates comprehensive cancer care center in Indore, Madhya Pradesh. The firm is also engaged in radiation business in Indore, Madhya Pradesh.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 30 Mar 2016
- Employees
- 5,504
- Website
- hcgel.com ↗
Leadership
Pay as last reported
- Dr. Basavalinga AjaikumarNon-Independent Non-Executive Chairman of the Board, since 2025₹60.0m
- Dr. Manish MattooChief Executive Officer, Executive Director, since 2025
- Ms. Sunu ManuelCompliance Officer, Company Secretary, since 2022₹6.1m
- Ms. Simrun MehtaNon-Executive Non-Independent Director
- Ms. Anjali RossiNon-Executive Non-Independent Director, since 2021₹15.0m
- Mr. Akshay TannaNon-Executive Non-Independent Director
- Mr. Pradip KanakiaNon-Executive Independent Director₹2.0m
- Mr. Bijou KurienAdditional Non-Executive Independent Director
- Mr. Rajiv MaliwalNon-Executive Independent Director₹2.0m
- Ms. Geeta MathurNon-Executive Independent Director₹2.0m
- Mr. Rajagoplan RaghavanNon-Executive Independent Director₹2.0m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 70
- Environment
- 73
- Social
- 80
- Governance
- 57
- Direct emissions (scope 1)
- 981.24 t
- Energy emissions (scope 2)
- 34,088.95 t
- Women in the workforce
- 49.33333%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- HCG operates the largest private cancer treatment network in India with multiple centers.
- Milann provides specialized fertility services including assisted reproduction and gynecological endoscopy.
- Triesta offers oncology diagnostics and biomarker research services in India.
Weaknesses
- The company has no presence in international markets beyond India.
- HCG's focus on cancer and fertility limits diversification across healthcare sectors.
- The firm's radiation business in Indore is limited to one location.
Opportunities
- Expanding HCG's cancer network to new Indian cities could increase market share.
- Growing demand for fertility treatments in India presents a significant opportunity.
- Triesta's biomarker research could lead to new diagnostic partnerships.
Threats
- Competition from established healthcare providers in India may reduce market share.
- Regulatory changes in the Indian healthcare sector could increase operational costs.
- Economic downturns might decrease patient spending on elective procedures.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.